Jazz Pharmaceuticals (Jazz Pharmaceuticals) Change In Inventory : $-13 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Change In Inventory?

Jazz Pharmaceuticals's change in inventory for the quarter that ended in Dec. 2023 was $-1 Mil. It means Jazz Pharmaceuticals's inventory increased by $1 Mil from Sep. 2023 to Dec. 2023 .

Jazz Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2023 was $-13 Mil. It means Jazz Pharmaceuticals's inventory increased by $13 Mil from Dec. 2022 to Dec. 2023 .

Jazz Pharmaceuticals's Total Inventories for the quarter that ended in Dec. 2023 was $597 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Jazz Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2023 was 514.29.

Inventory Turnover measures how fast the company turns over its inventory within a year. Jazz Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.18.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Jazz Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.60.

Jazz Pharmaceuticals Change In Inventory Historical Data

The historical data trend for Jazz Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Change In Inventory Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-32.79

-30.54

-48.86

-49.64

-13.42

Jazz Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															0.82	-6.27	-0.82	-4.93	-1.40

Jazz Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13 Mil.

Jazz Pharmaceuticals (NAS:JAZZ) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Jazz Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	604.433	/	107.243	*	365 / 4
	=	514.29

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Jazz Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	107.243	/	604.433
	=	0.18

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Jazz Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	604.433	/	1011.935
	=	0.60

Jazz Pharmaceuticals Change In Inventory Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals (Jazz Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (NAS:JAZZ) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

JAZZ:Mexico J7Z:Germany J7Z:Germany

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Executives

Jennifer E. Cook	director	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Mark Douglas Smith	director	C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Neena M Patil	officer: SVP, General Counsel	JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Patricia Carr	officer: VP, Finance& PAO	JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Heather Ann Mcsharry	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Patrick G Enright	director, 10 percent owner	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Norbert G Riedel	director	BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Catherine A. Sohn	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Rick E Winningham	director	901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Peter Gray	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Anne Oriordan	director	HOUSE 120, TAI HANG HAU VILLAGE, LOBSTER BAY, CLEARWATER BAY K3 HK
Kenneth W O'keefe	director	C/O BEECKEN PETTY O'KEEFE & COMPANY, 131 S. DEARBORN STREET, SUITE 2800, CHICAGO IL 60603
Mary Elizabeth Henderson	officer: SVP, Technical Operations	3170 PORTER DRIVE, PALO ALTO CA 94304
Renee D Gala	officer: EVP & CFO	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kim Sablich	officer: EVP & GM, North America	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005